Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ciclosporin A topical - BioNanoSim/Immune Pharmaceuticals

Next Previous
X
Search
Drug Profile

Ciclosporin A topical - BioNanoSim/Immune Pharmaceuticals

Alternative Names: CsA - Immune Pharmaceuticals; Cyclosporine-A - Immune Pharmaceuticals; Nano-cyclosporine A - Immune Pharmaceuticals; Nano-formulated cyclosporine A - Immune Pharmaceuticals; Nanocyclo; NanoCyclo - Immune Pharmaceuticals

Latest Information Update: 28 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hebrew University of Jerusalem
  • Developer Hebrew University of Jerusalem; Immune Pharmaceuticals Inc
  • Class Anti-inflammatories; Antineoplastics; Antipsoriatics; Antirheumatics; Ciclosporins; Eye disorder therapies; Heart failure therapies; Neuroprotectants
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Atopic dermatitis; Psoriasis

Most Recent Events

  • 28 Dec 2024 No recent reports of development identified for preclinical development in Atopic-dermatitis in Israel (Topical)
  • 28 Dec 2024 No recent reports of development identified for preclinical development in Psoriasis in Israel (Topical)
  • 13 Dec 2022 Ciclosporin A is still in preclinical trials for Atopic dermatitis and Psoriasis in Israel (Immune Pharmaceuticals pipeline, December 2022)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top